ConductScience.org, home

Paper42680902

New thinking for the next generation of antimalarials.

Asiki H and 4 others. EMBO Mol Med, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. New thinking for the next generation of antimalarials. Papers, record 42680902. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42680902

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
New thinking for the next generation of antimalarials.
PubMed
Journal
EMBO Mol Med
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-10-15
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Asiki HHannah
2Hlozek JJason
3Wicht KJKathryn Jhttps://orcid.org/0000-0001-6145-9956
4Woodland JGJohn Ghttps://orcid.org/0000-0001-6273-5596
5Chibale KKelly

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AntimalarialsMajor topic
Drug DiscoveryMajor topic
MalariaMajor topic
PlasmodiumMajor topic
Humans
Animals
Drug Repositioning
Drug Resistance

Source PubMed

Download CSV of topics

References149

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139402081Computational approach for decoding malaria drug targets from single-cell transcriptomics and finding potential drug molecule.Sci Rep2024https://conductscience.org/library/papers/39402081PubMed
224950358
Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
Vaccine2014https://conductscience.org/library/papers/24950358PubMed
342287204The Human Chk1 Inhibitor CHIR-124 Shows Multistage Activity against the Human Malaria Parasite Plasmodium falciparum via Polypharmacological Inhibition of PfArk1 and Hemozoin Formation.ACS Chem Biol2026https://conductscience.org/library/papers/42287204PubMed
4223905383,5-Diaryl-2-aminopyridines as a novel class of orally active antimalarials demonstrating single dose cure in mice and clinical candidate potential.J Med Chem2012https://conductscience.org/library/papers/22390538PubMed
537652975Antimalarial drug discovery: progress and approaches.Nat Rev Drug Discov2023https://conductscience.org/library/papers/37652975PubMed
626030447Plasmodium falciparum genetic crosses in a humanized mouse model.Nat Methods2015https://conductscience.org/library/papers/26030447PubMed
734553687Common host variation drives malaria parasite fitness in healthy human red cells.Elife2021https://conductscience.org/library/papers/34553687PubMed
836266336CRISPR-based oligo recombineering prioritizes apicomplexan cysteines for drug discovery.Nat Microbiol2022https://conductscience.org/library/papers/36266336PubMed
928688800Protein Degradation Systems as Antimalarial Therapeutic Targets.Trends Parasitol2017https://conductscience.org/library/papers/28688800PubMed
1033590753Plasmodium Kinases as Potential Drug Targets for Malaria: Challenges and Opportunities.ACS Infect Dis2021https://conductscience.org/library/papers/33590753PubMed
1139441986Targeting PfCLK3 with Covalent Inhibitors: A Novel Strategy for Malaria Treatment.J Med Chem2024https://conductscience.org/library/papers/39441986PubMed
1227247245Phenotypic Screens in Antimalarial Drug Discovery.Trends Parasitol2016https://conductscience.org/library/papers/27247245PubMed
1336856421Novel Transmission-Blocking Antimalarials Identified by High-Throughput Screening of Plasmodium berghei Ookluc.Antimicrob Agents Chemother2023https://conductscience.org/library/papers/36856421PubMed
1434523908Prioritization of Molecular Targets for Antimalarial Drug Discovery.ACS Infect Dis2021https://conductscience.org/library/papers/34523908PubMed
1531170268Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents.PLoS Pathog2019https://conductscience.org/library/papers/31170268PubMed
1621957167Disclosure of clinical trial results when product development is abandoned.Sci Transl Med2011https://conductscience.org/library/papers/21957167PubMed
1735439421The Ascension of Targeted Covalent Inhibitors.J Med Chem2022https://conductscience.org/library/papers/35439421PubMed
1823511784Phenotypic vs. target-based drug discovery for first-in-class medicines.Clin Pharmacol Ther2013https://conductscience.org/library/papers/23511784PubMed
1931978322The Antimalarial Natural Product Salinipostin A Identifies Essential α/β Serine Hydrolases Involved in Lipid Metabolism in P. falciparum Parasites.Cell Chem Biol2020https://conductscience.org/library/papers/31978322PubMed
2039607932Systematic in vitro evolution in Plasmodium falciparum reveals key determinants of drug resistance.Science2024https://conductscience.org/library/papers/39607932PubMed

See all 149 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42680902

GET https://conductscience.org/api/papers/v1/42680902/references?page=2